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absTraCT
Pathogenic species of Leptospira lead to a zoonotic disease called leptospirosis, which is spread worldwide. A 
major topic of investigation is to detect the antigens that induce an immune response and to utilize them in diagnostic 
kits or vaccine development. The outer membrane proteins (OMPs) of Leptospira are potential candidates for this 
purpose. Lipl41 is an OMP that is conserved among pathogenic Leptospira. The aim of this study was to express 
and purify the Lipl41 recombinant protein in Iranian isolates. All collected Lipl41 protein sequences were compared 
and analyzed using bioinformatics tools from NCBI databases. Complete codon sequences of the Iranian pattern of 
Lipl41 recombinant protein were codon optimized and sub-cloned into a pET32a+ expression vector, and transformed 
into Escherichia coli BL21 (DE3). Optimal expression of recombinant Lipl41 (47kDa) was achieved post-induction 
with IPTG within the inclusion body. It was then purified by denaturation using serial concentrations of urea, and the 
recombinant protein was confirmed by western blot. In this study, sufficient amounts of Lipl41 were expressed and 
purified to be used for the development of a diagnostic kit and subunit vaccine.
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countries (LOMAR et al., 2000). The clinical 
syndromes in humans are difficult to differentiate. 
The manifestations can range from a moderate 
fever similar to flu, to more serious illnesses 
presenting with hemorrhage, jaundice, myalgia, 
introduction 
Leptospirosis is a global zoonotic disease caused 
by pathogenic Leptospira. It is regularly prevalent 
in tropical, subtropical and humid parts with high 
levels of rainfall (ADLER and MOCTEZUMA, 
2010), mostly in poor urban areas in developing 
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renal dysfunction, and aseptic meningitis, which 
can lead to death in some patients (SEIJO et al., 
2002; KHAKI, 2016a). After infection, Leptospira 
can colonize the renal tubules of a number of wild 
and domestic animals for prolonged periods, and 
are discharged through urine into the environment 
(BURRIEL et al., 2003; MONAHAN et al., 2008). 
Humans are usually contaminated directly or 
indirectly by infected animal urine. (MCBRIDE 
et al., 2005; INANLOU et al., 2015). Due to the 
widespread animal reservoirs, eradication of 
leptospirosis is problematic (ZAKERI et al., 2010). 
Despite vaccination, the disease still survives 
(KOIZUMI and WATANABE, 2005). Although 
vaccine development is the main strategy to 
remove the illness, current drawbacks of whole-
cell vaccines include short duration of immunity, 
serovar specificity and side effects (VEDHAGIRI 
et al., 2009; LIN et al., 2016). Thus, the production 
of an efficient vaccine with lower levels of toxicity 
is essential to control and eliminate this disease 
(DELLAGOSTIN et al., 2011). Many studies 
on the development of recombinant vaccines 
against leptospirosis have used conserved outer 
membrane proteins (OMPs) such as Lipl21, Lipl32, 
Lipl41, Ompl1, etc (VEDHAGIRI et al., 2009; 
MEGUDESWARAN et al., 2014; LIN et al., 2016; 
CHANDY et al., 2017). OMPs revealed on the 
surface are among the most impressive antigens that 
can affect immune responses throughout the course 
of the disease. (FLANNERY et al., 2001; OLIVEIRA 
et al., 2015). There are three classes of leptospiral 
OM proteins (OMPs) which consist of lipoproteins, 
trans membrane proteins and peripheral membrane 
proteins (SHANG et al., 1996; ADLER et al., 
2011). Regarding abundance, Lipl41 (41kDa) is 
the third among OM lipoproteins (CULLEN et al., 
2005). This protein is an immunogenic antigen and 
expressed only in the pathogenic Leptospira, but 
notably absent in nonpathogenic species (KHAKI 
et al., 2016b), and has been considered as an 
indicator in serodiagnosis of the disease (HAAKE 
et al., 1999; MARIYA et al., 2006). Results of 
earlier studies have also shown that Lipl41 is 
surface exposed and expressed during infection in 
mammalian hosts (SENTHILKUMAR et al., 2007; 
KING et el., 2013). Therefore, it may be considered 
a potential subunit vaccine candidate against 
leptospirosis and, moreover, could be useful in a 
diagnostic kit. (SRIVASTAVA, 2006; SRIKRAM et 
al., 2011). Hence, in this present study, our aim was 
to express and purify Iranian isolates of the Lipl41 
r protein of pathogenic Leptospira to develop a 
recombinant antigen. 
Materials and methods
Bioinformatics studies and generation of 
Lipl41 construct. Twenty-seven complete coding 
sequences of Lipl41 protein 1065bp (355aa) from 
six prevalent pathogenic Leptospira serovars, 
consisting of eleven from Iran, such as: serovar 
Canicola, serovar Autumnalis, serovar Hardjo, 
serovar Icterohaemorrhagiae, serovar Pomona, 
serovar Grippotyphosa, and sixteen lipl41 sequences 
from other countries available in NCBI database 
were collected from GenBank (https://www.ncbi.
nlm.nih.gov/GenBank) by using the BLAST online 
software (https://blast.ncbi.nlm..nih.gov/Blast.cgi) 
(Table 1). All collected protein sequences were 
compared and analyzed using bioinformatics tools 
such as MegAlign software. 
A partial sequence of Lipl41, including coding 
sequences of amino acids number 21 to 355 
(1005 bp) minus signal peptide (first 20aa), was 
synthesized by General Biosystems, Inc, USA. In 
addition, pET-32a+ was used to produce a 47kDa 
TRX-Lipl41 fusion protein. EcoR I- Sal I restriction 
sites were used for sub cloning into the pET-32a+ 
vector and the His-Tag sequence was considered for 
affinity purification. Codon optimization of Lipl41 
was carried out for better expression in Escherichia 
coli with pET32a+ expression vector. 
Expression. The recombinant plasmid of pET32a- 
Lipl41 was transformed into E. coli BL21 (DE3) as 
the host strain, on LB Agar containing 50 μg/mL 
ampicillin by the heat shock method (SAMBROOK 
and RUSSEL, 2001). Then a matrix plate was sub-
cultured, and one single colony of it was cultured 
in 5 mL LB broth medium, supplemented with 5 
μg/mL Ampicillin at 37 °C overnight. One mL of 
this suspension was inoculated onto 50 mL 2YT/
AMP broth medium for induction. When the optical 
density reached 0.6 A600, the recombinant plasmid 
was induced with Isopropyl- β-D-Thio Galacto 
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Pyranoside (IPTG). Sampling was performed 
before and after induction at different times (0 - 4 
h and also16 h). Different incubation temperatures 
(22 and 37 °C) and various concentrations (0.1 to 
0.5mM) of IPTG were analyzed. The induced cells 
were harvested by centrifuge at 5000 g at 4 °C for 
5 min. The pellets were suspended in 1XPBS (137 
mMNaCl, 2 mMKH2PO4, 10 mM Na2HPO4, 2.7 
mMKCl, pH 7.4) with sample buffer added (5× 
solution of 250 mMTris.HCl, pH 6.8, 10% SDS, 
30% (v/v) Glycerol, 10 mM DTT, 0.05% (w/v) 
bromophenol blue, 2-Mercaptoethanol), boiled for 
5 min, then analyzed by SDS-PAGE using a 10% 
polyacrylamide gel along with Unstained protein 
markers (Thermo Scientific, USA). The gel was 
stained for 2 hr by standard Coomassie brilliant 
blue R-250 and distained with 45% methanol, 
10% acetic acid glacial solution. Induced cells 
were resuspended in PBS with 10mM imidazole, 
and sonicated five times for 1 minute on ice with 
one minute intervals. After that, Phenyl Methyl 
Sulfonyl Fluoride (PMSF) was added to inhibit 
protease activity. The cell lysate was centrifuged at 
15,000 g at 4 °C for 15 min. The supernatant and 
pellet analyzed by SDS-PAGE. 
Table 1. List of LipL41 sequences of Leptospira interrogans used in this study
Protein Id Serovar Strain Country
AAT48499.1 Australis 65-9 China
BAE48274.1 Australis Akiyami C Japan
AAV88037.1 Australis 65-9 China
AHW80383.1 Autumnalis RTCC2802 Iran
AAT48498.1 Autumnalis Lin 4 China
BAE48272.1 Autumnalis Akiyami A Japan
AHW80387.1 Canicola RTCC2824 Iran
AAT48495.1 Canicola Lin China
AHX26958.1 Canicola RTCC2805 Iran
AAT65971.1 Canicola -------- India
AHW80384.1 Hardjo RTCC2810 Iran
AAT65970.1 Hardjo -------- India
AHX26962.1 Hardjo RTCC 2821 Iran
AHW80386.1 Icterohaemorrhagiae RTCC2823 Iran
AHX26960.1 Icterohaemorrhagiae RTCC2812 Iran
ACV53831.1 Icterohaemorrhagiae -------- India
AAS21814.1 Kremastos Kremastos USA
AHW80385.1 Pomona RTCC2822 Iran
AHX26961.1 Pomona RTCC 2815 Iran
AAU04601.1 Pomona Luo China
AAV88038.1 Pomona Luo China
AAS21818.1 Pomona PomonaRZ11 USA
AHA11954.1 Pomona Pomona P Argentina
AHW80388.1 Grippotyphosa RTCC2825 Iran
AFH54361.1 Grippotyphosa Moskva V India
AAT48501.1 Grippotyphosa Lin 6 China
AHX26959.1 Grippotyphosa RTCC 2808 Iran
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Protein purification and immunoblotting. The 
rLip41 protein was purified from the post sonication 
pellets under denaturation conditions using serial 
concentrations of 1 to 8M urea in PBS buffer at 37 
°C. The post sonication pellets were suspended in 5 
mL 1M urea and shacked for 1h in 37 °C. Washing 
with 2 to 5 M urea was done for 1 hour, and the 
6 to 8 M concentrations of urea were incubated 
overnight. Purified proteins were dialyzed in 1X 
PBS and assessed by 10% SDS-PAGE, then stored 
at -70 °C for further analysis.
Western-blotting was performed. The blocking 
step was performed by 1% BSA in PBS containing 
0.1% Tween 20, then probed with a HRP conjugated 
anti-6x His-Tag antibodies (Abcam, USA) (diluted 
1:5,000). 4-choloro-1-naphthol was used for 
developing the protein band.
Protein assay. Quantitation of recombinant 
protein was performed by Bradford protein assay. 
To achieve a standard curve, various concentrations 
of 0.25 mg/mL BSA (Bovine Serum Albumin) 
were utilized. Ten dilutions of BSA were prepared 
in range of 0 to 10 µg/μL protein as a standard 
lane in deionized water. 200 μL Bradford reagent 
was added to all dilutions containing BSA and 
recombinant protein up to 1 mL final volume.
results
Phylogenetic analysis of full length LipL41 
proteins (355aa) showed 0.8 percent divergence 
between six serovars of leptospira interrogans in 
Iran and the other countries (as shown in Fig. 1). 
Multiple Alignment of LipL41 protein sequences 
using MegAlign software identified significant 
amino acid substitutions had taken place among 
the serovars. Notably, 20 different amino acid 
substitutions were detected, 8 of which were 
observed among some Iranian isolates, as stipulated 
below: in Iranian Leptospira serovar Grippothyphosa 
(AHW80388.1) and (AHX26959.1) isolates, 3 
amino acid substitutions were found in residues 
146, 212 and 312 (I146→ V146, F212→ Y212 and 
T312→A312). Furthermore, in serovar Pomona 
(AHW80385.1) and serovar Hardjo (AHX26962.1) 
one amino acid substitution was observed in 
residue 204 (V204→ I204). On the basis of these 
polymorphisms, the local Lipl41protein pattern was 
used to design the construct. 
Fig. 2 . SDS-PAGE (12%) analysis of the expressed 
rLipl41 protein in BL21 (DE3) which was induced 
by 0.1mM IPTG at different times. Lane 1: Unstained 
protein molecular weight marker (kDa), (Thermo, 
scientific). Lane2: non-induced cell lysate. Lane 3: 
induced (1h) cell lysate. Lane 4: induced (3 h) cell 
lysate. Lane 5: induced (4 h) cell lysate. Lane 6: 
induced (over-night) cell lysate.
Recombinant protein was induced at different 
times, temperatures and various concentrations of 
IPTG. The protein electrophoresis by SDS-PAGE 
analysis revealed a distinct band that corresponded 
to successful induction of full-length 47 kDa Lipl41 
protein. However, maximum expression of the 
Lipl41 recombinant protein was observed at 4 h 
Fig. 1. Phylogenetic analysis of six leptospira 
interrogans serovars, including eleven from Iran and 
sixteen from other countries submitted to GenBank 
(protein Id). The phylogenetic tree based on LipL41 
protein sequences used Megalign software.
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post induction incubation at 37 °C in the presence 
of 0.1 mM IPTG (Fig. 2). 
Analysis of the cell lysate post-sonication 
demonstrated that the recombinant protein was 
mostly found in the pellet, not in the supernatant.
Fig. 3. Analysis of the purified Lipl41 recombinant 
protein (47kDa) with SDS PAGE followed by 
Coomassie blue staining. Lane 1: unstained protein 
molecular weight marker (kDa), (Thermo, scientific). 
Lane 2: purified Lipl41 protein with 6M urea 
concentration. Lane 3: purified Lipl41 protein with 8M 
urea concentration. Lane 4: purified Lipl41 protein with 
7M urea concentration.
Fig. 4. Western blot analysis of the purified Lipl41 
recombinant protein using HRP-conjugated Anti His-
Tag antibody. Lane 1: Lipl41Purified recombinant 
protein (47kDa) in SDS PAGE. Lane 2: Prestained 
Protein Molecular Weight ladder (Thermo, scientific).
The protein was purified after washing in serial 
concentrations of urea in PBS (1 to 5M) and then 
solubilized in (6 to 8M) at 37 °C. The results of 
protein purification in all three concentrations 
of urea (6 to 8M) showed a sharp single band (at 
47 KDa). Moreover, the protein obtained from 
purification with an urea concentration of 6M had 
the maximum protein concentration (Fig. 3). The 
yield of purified recombinant protein was estimated 
to be 28.3 mg/mL.
Western blot confirmed the distinct 47 kDa band 
(Fig. 4).
discussion
In recent years many studies have been 
conducted on the identification, expression, 
and characterization of the leptospiral OMPs, 
such as OmpL1, Omp52, LipL21, LipL36, 
LipL41, etc (HAAKE and MATSUNAGA, 2002; 
SENTHILKUMAR et al., 2007; DEZHBORD et 
al., 2014; HOSEINPUR et al., 2015; SOLTANI 
et al., 2015). Some other studies revealed that, 
unlike leptospiral LPS, OMPs are generally 
well conserved, not serovar specific and able to 
induce cross-protective immunity (KOIZUMI and 
WATANABE, 2005; OLIVEIRA et al., 2015). In 
addition, leptospiral OMPs are commonly exposed 
on the surface and are among the first antigens that 
interact with host immune cells (CULLEN et al., 
2002; NALLY et al., 2007).
One of the most important OMPs expressed 
during human infection is Lipl41, a 41kDa 
lipoprotein that is highly conserved in pathogenic 
Leptospira species. (MEGUDESWARAN et al., 
2014) Furthermore, Lipl41 has been determined as 
a hemin-binding protein (LIN et al., 2013), and is 
one of the key virulence factors involved in host-
pathogen contact. Thus, it appears that Lipl41 may 
play an important role in inducing immunological 
responses in the host (GUERREIRO et al., 2001). 
According to previous reports, the use of Lipl41 
of pathogenic Leptospira in a multi-serovar ELISA 
enhanced the sensitivity of the test (THEODORIDIS 
et al., 2005; NATARAJASEENIVASAN et al., 2008). 
Another investigation conducted by MARIYA et al 
in 2006 demonstrated that Lipl41 antigen in ELISA 
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is a possible candidate for serodiagnosis of bovine 
leptospiral infection. Moreover, earlier studies 
indicated that this protein is expressed throughout 
acute infection (KING et al., 2013), and may be 
susceptible to the host immune defenses, either by 
itself or in combination with OmpL1 (HAAKE et 
al., 1999; LIN et al., 2011). 
Consequently, Lipl41 could be considered a 
genus-specific antigen for improvement of new 
broad spectrum vaccines and serodiagnostic 
techniques against leptospirosis.
Therefore, our study focused on the expression 
and purification of Lipl41 protein of Iranian 
pathogenic Leptospira in E. coli. We used BLAST 
software to gather all the protein sequences of Lipl41 
of pathogenic Leptospira from different serovars 
from Iran and other countries available in the NCBI 
database. A significant finding in our study was the 
detection of 8 amino acid subsituations in some 
Iranian isolates, which, to our knowledge, have not 
been reported in the literature. Gene construct was 
then designed according the pattern of local Lipl41 
protein prevalent pathogenic Leptospira isolates. 
Induction of the recombinant protein using 
various concentrations of IPTG was performed 
at different times and temperatures, which 
demonstrated the maximum expression of Lipl41 
recombinant protein in BL21 (DE3) at 37 °C and 
0.1mM IPTG at 4 hours post induction. A high 
level of expression of Lipl41 was observed (28.38 
mg/mL). Hence, under these conditions, optimal 
recombinant protein purification was achieved as 
one distinct band, with an approximate molecular 
weight of 47kDa. On the basis of our results, 
the blotted protein (using HRP-conjugated Anti 
anti-6x His-Tag Ab) verified the presence of the 
recombinant Lipl41protein as illustrated in Fig. 4.
Some researchers have obtained high expression 
rates of this protein using either pET series 
(MEGUDESWARAN et al., 2014; LIN et al., 2016) 
or other similar expression vectors (MARIYA et al., 
2006; KING et al., 2013; LIN et al., 2013). Solubility 
is an important factor for producing recombinant 
proteins in heterologous expression systems. Due to 
differences in folding structure, soluble recombinant 
proteins are usually considerably easier to purify 
compared with insoluble ones (COSTA et al., 
2014). Despite the use of the TRX tag sequence 
during gene construction to enhance solubility, a 
significant amount of the recombinant protein was 
found in the inclusion body, while lesser quantities 
were detected in the supernatant, and expressed 
in the insoluble form. These results agreed with 
other studies where the over expressed Lipl41 was 
observed mostly in the inclusion body, and purified 
under denaturing conditions (MARIYA et al., 2006; 
KING et al., 2013; LIN et al., 2013). Although in 
one report this protein was solubilized with 6M 
guanidine, (HAAKE et al., 1999), in this study we 
used 1-8 M urea according to the manual protocol 
(to be under published). This provided an efficient 
and cost-effective method which is applicable for 
purification of Lipl41 insoluble proteins.
Conclusion 
In conclusion, this study demonstrated 0.8 percent 
divergence between Lipl41 protein sequences 
of Iranian and foreign Leptospira interrogans 
serovars. 8 amino acid subsituations were identified 
among local serovars which were used to design 
the gene construct. It was successfully expressed in 
E. coli BL 21(DE3) and purified by denaturation, 
using serial concentrations of urea.
The presence of purified protein was confirmed 
with SDS-PAGE analysis and western blotting.
Therefore, the possible immunogenicity of 
this recombinant protein was demonstrated, and 
it may have the potential to induce effective 
protective immunity against leptospirosis in the 
future. However, the serodiagnostic ability of 
this recombinant protein as a capture antigen in 
the ELISA method in animal and human subjects 
requires further investigation.
acknowledgements
This study was supported by a grant (Number: 12-18-18-
106-96045-961023) from Razi Vaccine and Serum Research 
Institute, Agricultural Research, Education and Extension 
Organization (AREEO), Karaj, Iran.
references
ADLER, B., A. DE LA PEÑA MOCTEZUMA (2010): 
Leptospira and leptospirosis. Vet. Microbiol. 140, 287-296.
 DOI: 10.1016/j.vetmic.2009.03.012
N. Golab et al.: Expression and purification of the Lipl41, a surface–exposed lipoprotein antigen of pathogenic Leptospira spp.
Vet. arhiv 90 (3), 297-305, 2020 303
ADLER, B., M. LO, T. SEEMANN, G. L. MURRAY (2011): 
Pathogenesis of leptospirosis: the influence of genomics. 
Vet. Microbiol. 153, 73-81.
 DOI: 10.1016/j.vetmic.2011.02.055
BURRIEL, A. R., C. DALLEY, M. J. WOODWARD (2003): 
Prevalence of Leptospira species among farmed and 
domestic animals in Greece. Vet. Rec. 153, 146-148. 
 DOI: 10.1136/vr.153.5.146
CHANDY, S., L. KIRUBANANDHAN, P. HEMAVATHY, A. 
M. KHADEEJA, S. J. KURIAN, K. VENKATARAMAN, 
K. MØRCH, D. MATHAI, A. MANOHARAN (2017): 
Serovar prevalence of Leptospira in semirural India and 
the development of an IgM-based indirect ELISA. J. Infect. 
Dev. Ctries. 11, 234-241. 
 DOI: 10.3855/jidc.8067
COSTA, S., A. ALMEIDA, A. CASTRO, L. DOMINGUES 
(2014): Fusion tags for protein solubility, purification, and 
immunogenicity in Escherichia coli: the novel Fh8 system. 
Front. Microbiol. 5, 63. 
 DOI: 10.3389/fmicb.2014.00063
CULLEN, P. A,. S. J. CORDWELL, D. M. BULACH, D. A. 
HAAKE, B. ADLER, (2002): Global analysis of outer 
membrane proteins from Leptospira interrogans serovar 
Lai. Infect. Immun. 70, 2311-2318. 
 DOI: 10.1128/iai.70.5.2311-2318.2002
CULLEN, P. A., X. XU, J. MATSUNAGA, Y. SANCHEZ, 
A.I. KO, D. A. Haake, B. Adler (2005): Surfaceome of 
Leptospira spp. Infect. Immun 73, 4853-4863.
  DOI: 10.1128/IAI.73.8.4853-4863
DELLAGOSTIN, O. A., A. A. GRASSMANN, D.D. 
HARTWIG, S. R. FELIX, E. F. DA SILVA, A. J. McBRIDE 
(2011); Recombinant vaccines against leptospirosis. Hum. 
Vaccin. 7, 1215-24.
  DOI: 10.4161/hv.7.11.17944
DEZHBORD, M., M. ESMAELIZAD, P. KHAKI, F. FOTOHI, 
A. ZAREHPARVAR MOGHADDAM (2014): Molecular 
identification of the ompL1 gene within Leptospira 
interrogans standard serovars. J. Infect. Dev. Ctries. 8, 
688-693. 
 DOI: 10.3855/jidc.3174
FLANNERY, B., D. COSTA, F. P. CARVALHO, H. 
GUERREIRO. J.  MATSUNAGA, E. D. DA SILVA, A. G. 
FERREIRA, L. W. RILEY, M. G. REIS, D. A. HAAKE, 
A. L. KO (2001): Evaluation of recombinant Leptospira 
antigen-based Enzyme-Linked Immunosorbent assays for 
the serodiagnosis of Leptospirosis. J. Clin. Microbiol. 39, 
3303-3310. 
 DOI: 10.1128/JCM.39.9.3303-3310.2001.
GUERREIRO, H., J. CRODA, B. FLANNERY, M. MAZEL, J. 
MATSUNAGA, M. GALVÃO REIS, P. N. LEVETT, A. I. 
KO, D. A. HAAKE (2001): Leptospiral proteins recognized 
during the humoral immune response to leptospirosis in 
humans. Infect. Immun. 69, 4958-4968. 
 DOI: 10.1128/IAI.69.8.4958-4968.2001
HAAKE, D. A., M. K. MAZEL, A. M. MCCOY, F. 
MILWARD, G. CHAO, J. MATSUNAGA, E. A. WAGAR 
(1999): Leptospiral outer membrane proteins Ompl1 
and Lipl41exhibit synergistic immunoprotection. Infect. 
Immun. 67, 6572-6582. 
 DOI: 0019-9567/99/$04.00+0
HAAKE, D. A., J. MATSUNAGA (2002): Characterization 
of the leptospiral outer membrane and description of three 
novel leptospiral membrane proteins. Inf. Immun. 70, 
4936-4945. 
 DOI: 10.1128/iai.70.9.4936-4945.2002
HOSEINPUR, H., P. KHAKI, M. NOOFELI, S. MORADI-
BIDHENDI (2015): Molecular detection of pathogenic 
leptospiral serovars by PCR, based on lipL21 gene. Arch. 
Razi Inst. 70, 223-227. 
 DOI: 10.7508/ari.2015.04.001
INANLOU, F., P. KHAKI, N. MOHAMMADPOUR, S. 
MORADI BIDHENDI, H. ZOLFAGHARIAN, Y. F. 
CHANG, M. R. BAZRAFSHAN, F. SARAEI (2015): 
Preparation of microspheres containing leptospiral antigen 
using biodegradable alginate epolymers. Vet. arhiv 85, 
395-406
KHAKI, P. (2016a): Clinical laboratory diagnosis of human 
leptospirosis, Int. J. Enteric. Pathog. 4: e31859. 
 DOI: 10.17795/ijep31859.
KHAKI, P., S. MORADIBIDHENDI, Y. F. CHANG, M. S. 
SOLTANI, K. TADAION (2016b): Amplification and 
cloning of a gene encoding a 41kDa outer membrane 
protein (LipL41) of Leptospira interrogans serovar 
Canicola. Infect. Epidemiol. Med. 2, 5-7. 
 DOI: 10.7508/iem.2016.03.002
KING, A. M., T. BARTPHO, R. W. SERMSWAN, D. M. 
BULACH, A. ESHGHI, M.PICARDEAU, B. ADLER, G. 
L. MURRAY (2013): Leptospiral outer membrane protein 
Lipl41 is not essential for acute leptospirosis but requires a 
small chaperone protein, Lep, for stable expression. infect. 
Immun. 81, 2768-2776.
 DOI: 10.1128/iai.00531-13
KOIZUMI, N., H.WATANABE (2005): Leptospirosis vaccines: 
past, present, and future. J. Postgrad. Med. 51, 210-4.
LIN, X., A. SUN, P. RUAN, Z. ZHANG, J. YAN (2011): 
Characterization of conserved combined T and B cell 
epitopes in leptospira interrogans major outer membrane 
proteins OmpL1 and LipL41. BMC Microbiol. 11, 21.
 DOI: 10.1186/1471-2180-11-21
LIN, M. H., Y. C. CHANG, C. D. HSIAO, S. H. HUANG, 
M. S. WANG, Y. C. KO, C. W. YANG, Y. J. SUN (2013): 
LipL41, a hemin binding protein from Leptospira 
santarosai serovar Shermani. PLOS ONE. 8(12) 
 DOI: 10.1371/journal.pone.0083246.
LIN, X., G. XIAO, D. LUO, L. KONG, X. CHEN, D. SUN, J. 
YAN (2016): Chimeric epitope vaccine against Leptospira 
interrogans infection and induced specific immunity in 
guinea pigs. BMC Microbiol. 16, 241. 
 DOI: 10.1186/s12866-016-0852-y
N. Golab et al.: Expression and purification of the Lipl41, a surface–exposed lipoprotein antigen of pathogenic Leptospira spp.
Vet. arhiv 90 (3), 297-305, 2020304
LOMAR, A. V., D. DIAMENT, J. R. TORRES (2000): 
Leptospirosis in Latin America. Infect. Dis. Clin. North 
Am. 14, 23-39.
 DOI: 10.1016/S0891-5520(05)70216-6
McBRIDE A. J., D. A. ATHANAZIO, M. G. REIS, A. I. KO 
(2005): Leptospirosis. Curr. Opin. Infect. Dis. 18, 376-86.
 DOI: 10.1097/01.qco.0000178824.05715.2c
MARIYA, R., P. CHAUDHARY, A. A. KUMAR, E. 
THANGAPANDIAN, R. AMUTHA, S. K. SRIVASTAVA 
(2006): Evaluation of a recombinant LipL41 antigen of 
Leptospira interrogans serovar Canicola in ELISA for 
serodiagnosis of bovine Leptospirosis. Com. Immunol. 
Microbiol. Infect. Dis. 29, 269-277. 
 DOI: 10.1016/j.cimid.2006.06.007
MEGUDESWARAN, S. K., M. PARTHIBAN, S. 
RAJENDRAN, S. SENTHILKUMAR, G. RAVIKUMAR 
(2014): Evidence of cross reaction potential recombinant 
Leptospira LipL41 Protein. Indian. J. Biotechnol. 13, 57-
61.
MONAHAN, A. M., J. J. CALLANAN, J. E. NALLY (2008): 
Proteomic analysis of leptospira interrogans shed in urine 
of chronically infected hosts. Infect. Immun. 76, 4952-
4958.
 DOI: 10.1128/IAI.00511-08
NALLY, J. E., J. P. WHITELEGGE, S. BASSILIAN, D. R. 
BLANCO, M. A. LOVETT (2007): Characterization of 
the outer membrane proteome of Leptospira interrogans 
expressed during acute lethal infection. Infect. Immune. 
75, 766-773.
  DOI: 10.1128/IAI.00741-06.
NATARAJASEENIVASAN, K., P. VIJAYACHARI, S. 
SHARMA, A. P. SUGUNAN, J. SELVIN, S. C. SEHGAL 
(2008) Serodiagnosis of severe leptospirosis: evaluation 
of ELISA based on the recombinant OmpL1 or LipL41 
antigens of Leptospira interrogans serovar autumnalis. 
Ann. Trop. Med. Parasitol. 102, 699-708.
 DOI: 10.1179/136485908X355229
OLIVEIRA, T. L., A. A. GRASSMANN, R. A. SCHUCH, A. 
C. P. SEIXAS NETO, M. MENDONÇA, D. D HARTWIG, 
A. J. A. MCBRIDE, O. A. DELLAGOSTIN (2015): 
Evaluation of the Leptospira interrogans Outer Membrane 
Protein OmpL37 as a vaccine candidate. PLOS one. 10(11), 
e0142821. 
 DOI: 10.1371/journal.pone.0142821
SAMBROOK, J., D. W. RUSSEL (2001): Molecular Cloning. 
Cold Spring Harbor Laboratory Press, Heatshock.
SEIJO, A., H. COTO, J. SAN JUAN, J. VIDELA, B. 
DEODATO, B. CERNIGOI, O. G. MESSINA, O. COLLIA, 
D. DE BASSADONI, R. SCHTIRBU, A. OLENCHUK, 
G. D. DE MAZZONELLI, A. PARMA (2002): Lethal 
leptospiral pulmonary hemorrhage: an emerging disease in 
Buenos Aires, Argentina. Emerg. Infect. Dis. 8, 1004-1005.
 DOI: 10.3201/eid0809.010499
SENTHILKUMAR, T.  M.  A., M. SUBAT HRA, P. RAMADASS 
(2007): Evaluation of recombinant leptospiral antigen 
LipL41 in enzyme-linked immunosorbent assay and latex 
agglutination test for serodiagnosis of canine leptospirosis. 
Vet. arhiv 77, 475-484.
SHANG, E. S., T. A. SUMMERS, D. A. HAAKE (1996): 
Molecular cloning and sequence analysis of the gene 
encoding LipL41, a surface-exposed lipoprotein of 
pathogenic Leptospira species. Infect. Immun. 64, 2322-
2330.
SOLTANI, M. S., P. KHAKI, S. MORADI BIDHENDI, M. 
H. SHAHHOSSEINY (2015): Molecular characterization 
of the LipL41 gene of Leptospira interrogans vaccinal 
serovars in Iran. Arch. Razi Inst. 70, 145-150.
 DOI: 10.7508/ari.2015.03.001
SRIKRAM, A., K. ZHANG, T. BARTPHO, M. LO, D. E. 
HOKE, R. W. SERMSWAN, B. ADLER, G. L. MURRAY 
(2011): Cross-protective immunity against leptospirosis 
elicited by a live, attenuated lipopolysaccharide mutant. J. 
Infect. Dis. 203, 870-879. 
 DOI: 10.1093/infdis/jiq127
SRIVASTAVA, S. K (2006): Prospects of developing 
leptospiral vaccines for animals. Indian. J. Med. Microbiol. 
24, 331-336.
THEODORIDIS, D., J. BÖHMER, M. HOMUTH, K. 
STRUTZBERG-MINDER(2005): Development of a novel 
ELISA for serodiagnosis of Leptospirosis and additional 
detection of pathogenic Leptospira by polymerase chain 
reaction for veterinary routine diagnostics. Rev. Cubana. 
Med. Trop. 57, 49-50.
VEDHAGIRI, K., K. NATARAJASEENIVASAN, P. 
CHELLAPANDI, S. G. PRABHAKARAN, J. SELVIN, 
S. SHARMA, P. VIJAYACHARI (2009): Evolutionary 
implication of outer membrane lipoprotein-encoding genes 
ompl1, lipl32 and lipl41 of pathogenic leptospira species. 
Genom. Proteom. Bioinf. 7, 96-106. 
 DOI: 10.1016/S1672-0229(08)60038-8
ZAKERI, S, N. KHORAMI, Z. F. GANJI, N. SEPAHIAN, A. 
A. MALMASI, M. M. GOUYA, N. D. DJADID (2010): 
Leptospira wolffii, a potential new pathogenic Leptospira 
species detected in human, sheep and dog. Inf. Gen. Evol. 
10, 273-277.
 DOI: 10.1016/j.meegid.2010.01.001
N. Golab et al.: Expression and purification of the Lipl41, a surface–exposed lipoprotein antigen of pathogenic Leptospira spp.
Vet. arhiv 90 (3), 297-305, 2020 305
Received: 31 August 2019
Accepted: 21 May 2020
_____________________________________________________________________________
GoLab, N., P. KhaKi, N. harzaNdi, M. EsMaELizad, M. TEbiaNiaN: Ekspresija i pročišćavanje 
površinskog lipoproteinskog antigena Lipl41 iz patogenih bakterija roda Leptospira. Vet. arhiv 90, 297-305, 
2020.
 sažETaK
Patogene vrste Leptospira uzrokuju zoonotsku bolest leptospirozu koja je raširena u cijelom svijetu. Cilj istraživanja 
bio je dokazati antigene koji potiču imunosni odgovor i mogu se primijeniti u dijagnostičkim kompletima ili za razvoj 
cjepiva. Vanjska proteinska membrana (OMPs) leptospira potencijalni je kandidat za tu svrhu, a gen Lipl41 je dobro 
očuvan među patogenim leptospirama. Ekspresija i pročišćavanje rekombinantnog proteina Lipl41 provedeno je u 
izolatima iz Irana. Uspoređene su sve prikupljene sekvencije proteina Lipl41 i analizirane bioinformatičkim alatom 
iz baze podataka NCBI. Kompletne sekvencije kodona rekombinantnog proteina Lipl41 u izolatima su optimizirane, 
zatim subklonirane u  pET32a+ vektor i pretvorene u bakteriju Escherichia coli BL21 (DE3). Optimalna ekspresija 
rekombinantnog Lipl41 (47kDa) postignuta je post-indukcijski pomoću isopropyl β-d-1-thiogalactopyranoside 
(IPTG). Zatim je pročišćena denaturacijom što je uključilo  primjenu serijskih koncentracija ureje. Rekombinantni 
protein je potvrđen metodom western blot. Istraživanje potvrđuje mogućnost ostvarenja dostatne količine i ekspresije 
pročišćenog Lip141  da se može upotrijebiti za razvoj dijagnostičkih kompleta i subjediničnih cjepiva.
Ključne riječi:  rekombinirani protein Lipl41; ekspresija; pročišćavanje; patogena Leptospira_____________________________________________________________________________________________

